Saturday 17 October 2026 Export DCTH’s income statement to Excel — free account

Delcath Systems, Inc.

Delcath Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 129.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS fell 12.5% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.08 0.73 −4.93%

Follow DCTH

Alert me

Market cap: $513.9M
P/E: 1,408×
Fwd P/E: −17.8×
Dividend yield: —
F-score: 7/9
Altman Z: 13.26
Beneish M: −2.73
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.19

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 10.57%

Capital & Financial Ratios $m

Market Cap 513.89

Revenue 95.42

Net Income 0.53

Free Cash Flow 17.51

Net Debt (95.90)

Current Ratio 9.83

Debt/Equity 0.00

P/E ratio 1,408.00

Fwd P/E (17.80)

P/S ratio 5.30

P/B ratio 4.17

Past 5Y EPS Growth —

This Y EPS Growth (357.14%)

Next Y EPS Growth 67.20%

Next Y revenue growth 24.60%

Next 5Y EPS Growth 37.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 30.46%

10-year low 10-year high

P/B against its own 10 years 38.88%

10-year low 10-year high

EV/Sales against its own 10 years 26.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	33	53	91	96
Receivables	0	11	12	16
Inventory	3	7	10	12
Other	—	—	—	—
	37	74	120	131

	2023	2024	2025	Q'26
Payables	1	1	3	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	16	6	11	13

Compound Annual Growth %

	10y	5y	3y
Sales	47.51%	120.21%	215.30%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.17%	38.18%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	25	29	—	—	—
’25	20	24	21	21	85
’24	3	8	11	15	37
’23	1	0	0	1	2
’22	0	1	1	1	3
’21	0	1	1	2	4
’20	0	0	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	6	—	—	—
’25	2	7	5	8	23
’24	(10)	(4)	(4)	(1)	(19)
’23	(4)	(10)	(9)	(8)	(31)
’22	(6)	(6)	(5)	(7)	(25)
’21	(5)	(7)	(5)	(6)	(23)
’20	(5)	(8)	(5)	(5)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	5	—	—	—
’25	2	7	4	8	21
’24	(10)	(5)	(4)	(1)	(19)
’23	(4)	(10)	(9)	(8)	(31)
’22	(6)	(6)	(5)	(7)	(25)
’21	(5)	(7)	(5)	(6)	(23)
’20	(5)	(8)	(5)	(5)	(24)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	0.07	—	—	—
’25	0.03	0.07	0.02	(0.05)	0.07
’24	(0.45)	(0.48)	0.06	(0.11)	(0.93)
’23	(0.77)	(0.58)	(1.14)	(0.48)	(2.94)
’22	(1.00)	(1.18)	(0.92)	(0.86)	(4.12)
’21	(1.04)	(0.96)	(0.94)	(0.69)	(3.59)
’20	(108.07)	(1.90)	(1.16)	(0.61)	(8.35)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	97,560,976.00	10,566.83	161.00	20.75	5.15	7.00	2.34	2.25	3.70	8.12	Analyst estimates 2026–2028 Powerpack
	High	1,091,800,064.00	113,963,416.00	34,289.71	255.50	20.25	25.18	8.25	7.99	13.30	18.23
People
People	Employees	43	46	43	33	36	55	52	76	96	156
	Revenue/emp, $m	0.05	0.06	0.08	0.05	0.05	0.06	0.05	0.03	0.39	0.55
Income, $m
Income, $m	Revenue	2	3	3	2	2	4	3	2	37	85
	Gross margin, %	72.39	74.18	70.38	54.49	61.12	81.13	74.77	69.25	83.37	86.16
	EBT	(18)	(45)	(19)	(9)	(24)	(26)	(37)	(48)	(26)	4
	EBT margin, %	(902.16)	(1,661.77)	(564.19)	(561.96)	(1,467.56)	(721.49)	(1,342.70)	(2,308.86)	(70.92)	4.12
	Net income	(18)	(45)	(19)	(9)	(24)	(26)	(37)	(48)	(26)	3
	Depreciation	15	22	3	5	0	0	1	1	0	(1)
Per share, $
Per share, $	Revenue	415.00	0.00	89.19	61.00	0.57	0.50	0.31	0.13	1.30	2.38
	Earnings	(3,707.65)	(2,321,429.00)	(514.29)	(342.82)	(8.35)	(3.59)	(4.12)	(2.94)	(0.93)	0.08
	Cash flow	(2,961.04)	0.00	(385.65)	(914.63)	(7.89)	(3.16)	(2.81)	(1.93)	(0.66)	0.63
	Capex	(53.75)	0.00	(1.99)	(0.93)	(0.27)	(0.02)	(0.02)	0.00	(0.02)	(0.04)
	Free cash flow	(3,014.79)	0.00	(387.64)	(915.56)	(8.16)	(3.18)	(2.84)	(1.93)	(0.67)	0.59
	Book value	(310.42)	0.00	(391.07)	(245.44)	7.62	1.67	(0.66)	0.97	2.41	3.10
	Shares, m	0	0	0	0	3	7	9	16	29	36
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	126.25
	P/S	256,215.11	0.00	2.20	0.35	31.55	15.58	11.28	32.30	9.23	4.24
	P/B	0.00	0.00	0.00	0.00	2.35	4.63	0.00	4.23	4.99	3.25
	EV/Sales	256,202.42	0.40	1.18	(4.83)	14.35	12.22	9.82	17.53	7.85	3.20
	EV/FCF	(35,267.45)	(0.07)	(0.27)	0.32	(1.00)	(1.91)	(1.06)	(1.16)	(15.18)	13.01
Cash, $m
Cash, $m	Operating cash flow	(14)	(15)	(15)	(24)	(23)	(23)	(25)	(31)	(19)	23
	Capex	0	(1)	0	0	(1)	0	0	0	(1)	(2)
	Free cash flow	(14)	(16)	(15)	(24)	(24)	(23)	(25)	(31)	(19)	21
Balance, $m
Balance, $m	Working capital	(2)	0	(12)	(3)	22	25	1	21	68	109
	Total debt	13	—	2	2	0	15	8	—	—	—
	Net debt	(32)	(5)	(4)	(8)	(28)	(12)	(4)	(33)	(53)	(91)
	Shareholders’ equity	(1)	1	(15)	(6)	22	12	(6)	16	69	111
Returns, %
Returns, %	ROA	(70.51)	(206.88)	(244.38)	(84.34)	(99.13)	(75.71)	(143.21)	(168.85)	(45.81)	2.70
	ROIC	0.00	0.00	0.00	0.00	0.00	(153,318.75)	0.00	0.00	(50.00)	2.04
	ROE	(505.44)	11,242.36	269.57	83.39	(308.01)	(150.74)	(1,198.36)	(961.44)	(62.44)	3.00

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KIDS OrthoPediatrics Corp.	$589.3M	— (loss-making)	— (loss-making)	+15.43% (above 0%: growing)	n/m	+77.59% (above 0%: growing)	74.27%	(5.77%)	Compare
TCMD Tactile Systems Technology, Inc.	$527.6M	20.5×	22.7×	+8.61% (above 0%: growing)	+142.86% (above 0%: growing)	−86.53% (below 0%: shrinking)	76.25%	7.97%	Compare
SSII SS Innovations International, Inc.	$517.2M	— (loss-making)	— (loss-making)	+39.39% (above 0%: growing)	n/m	−16.62% (below 0%: shrinking)	50.94%	(16.29%)	Compare
DCTH Delcath Systems, Inc.	$513.9M	1,408×	— (loss-making)	+20.60% (above 0%: growing)	−12.50% (below 0%: shrinking)	−24.45% (below 0%: shrinking)	89.75%	8.22%
MASS 908 Devices Inc.	$491.5M	— (loss-making)	— (loss-making)	+23.31% (above 0%: growing)	n/m	+150.95% (above 0%: growing)	51.90%	(79.69%)	Compare
SGHT Sight Sciences, Inc.	$484.8M	— (loss-making)	— (loss-making)	+19.55% (above 0%: growing)	n/m	+26.71% (above 0%: growing)	91.39%	(16.62%)	Compare
BWAY Brainsway Ltd. Sponsored ADR	$475.8M	24.8×	— (loss-making)	+35.43% (above 0%: growing)	+40.00% (above 0%: growing)	−51.68% (below 0%: shrinking)	74.62%	13.98%	Compare
CERS Cerus Corporation	$455.5M	— (loss-making)	— (loss-making)	+5.28% (above 0%: growing)	n/m	−20.90% (below 0%: shrinking)	55.91%	(2.94%)	Compare
NPCE NeuroPace, Inc.	$438.7M	— (loss-making)	— (loss-making)	+17.05% (above 0%: growing)	n/m	−78.70% (below 0%: shrinking)	82.83%	(22.53%)	Compare
Median of peers	$488.1M	—	—	+18.30%	—	−18.76%	74.45%	(11.03%)

All 149 Medical Devices stocks →

Delcath Systems, Inc. (DCTH) key facts

Strength: Delcath Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 129.1% from fiscal 2024.
Delcath Systems, Inc. (DCTH) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DCTH traded at $14.08, a market capitalization of $513.9 million.
Return on equity was 3.00% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 13.26 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.